RxDoctor Payments Data

Kamran Mahmood, MD

Pulmonary Disease · Chicago, ILNPI 1992783377

Payments from drug & device makers

$8,482in general payments, 2019–2025

Across 26 payments — averaging $326.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$3K
  • Pulmonx Corporation$1K
  • Galvanize Therapeutics, Inc$461
  • Bard Peripheral Vascular, Inc.$109
  • Veran Medical Technologies, Inc.$84
  • plus $76 from 3 others

What the payments were for

  • Consulting fees$2,70032%
  • Grants$320%
  • Travel & lodging$1,72920%
  • Food & beverage$1,02112%
  • Education$3,00035%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,482 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$57,201
Medicare patients
220
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$39,799
Spiriva RespimatTiotropium Bromide23$12,464
Breo ElliptaFluticasone/Vilanterol13$5,431
Advair HfaFluticasone Propion/Salmeterol15$5,382
SymbicortBudesonide/Formoterol Fumarate19$4,792
Albuterol Sulfate HfaAlbuterol Sulfate23$541
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$170
Levofloxacin11$152
Azithromycin15$143
Prednisone19$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,700$45,22972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →